Cipla's wholly-owned subsidiary, Inzpera Healthsciences, is merging with Cipla. This amalgamation aims to unlock synergies, enhance cost efficiency, and boost overall shareholder value through resource consolidation. As Inzpera is fully owned, no new shares will be issued, ensuring no dilution for existing Cipla shareholders. The National Company Law Tribunal has...
Cipla is setting up a new 60:40 joint venture with Kemwell Biopharma in India. This strategic move involves an initial partner investment of up to INR 10 Cr into the new company, with Cipla investing INR 6 Cr for its 60% stake. The JV will focus on developing, manufacturing, and...
Cipla has completed the acquisition of a 100% stake in Inzpera Healthsciences Limited. With this move, Inzpera has now become a wholly-owned subsidiary of Cipla. This acquisition marks a strategic expansion for Cipla, aimed at bolstering its presence in key segments and integrating Inzpera's capabilities fully into its operations. While...
Cipla has fully acquired Inzpera Healthsciences Limited, buying a 100% stake for approximately ₹110.65 Cr. Inzpera specializes in pediatric pharmaceutical and wellness products. This strategic move significantly strengthens Cipla's product portfolio and expands its reach in the high-growth children's health segment. The acquisition aims to leverage Cipla's robust distribution network...
Cipla has invested approximately ₹5 Cr to acquire a 20% stake in iCaltech Innovations Private Limited, a Bangalore-based company focused on respiratory medical diagnostic products. This strategic investment strengthens Cipla's leadership in respiratory care, aiming to develop integrated healthcare solutions by combining its pharmaceutical expertise with iCaltech's advanced medical device...